Literature DB >> 23878394

Phosphorylation regulates FOXC2-mediated transcription in lymphatic endothelial cells.

Konstantin I Ivanov1, Yan Agalarov, Leena Valmu, Olga Samuilova, Johanna Liebl, Nawal Houhou, Hélène Maby-El Hajjami, Camilla Norrmén, Muriel Jaquet, Naoyuki Miura, Nadine Zangger, Seppo Ylä-Herttuala, Mauro Delorenzi, Tatiana V Petrova.   

Abstract

One of the key mechanisms linking cell signaling and control of gene expression is reversible phosphorylation of transcription factors. FOXC2 is a forkhead transcription factor that is mutated in the human vascular disease lymphedema-distichiasis and plays an essential role in lymphatic vascular development. However, the mechanisms regulating FOXC2 transcriptional activity are not well understood. We report here that FOXC2 is phosphorylated on eight evolutionarily conserved proline-directed serine/threonine residues. Loss of phosphorylation at these sites triggers substantial changes in the FOXC2 transcriptional program. Through genome-wide location analysis in lymphatic endothelial cells, we demonstrate that the changes are due to selective inhibition of FOXC2 recruitment to chromatin. The extent of the inhibition varied between individual binding sites, suggesting a novel rheostat-like mechanism by which expression of specific genes can be differentially regulated by FOXC2 phosphorylation. Furthermore, unlike the wild-type protein, the phosphorylation-deficient mutant of FOXC2 failed to induce vascular remodeling in vivo. Collectively, our results point to the pivotal role of phosphorylation in the regulation of FOXC2-mediated transcription in lymphatic endothelial cells and underscore the importance of FOXC2 phosphorylation in vascular development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23878394      PMCID: PMC3811871          DOI: 10.1128/MCB.01387-12

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  34 in total

1.  Small ubiquitin-like modifier (SUMO) modification mediates function of the inhibitory domains of developmental regulators FOXC1 and FOXC2.

Authors:  Theodora E Danciu; Sergey Chupreta; Osvaldo Cruz; Jennifer E Fox; Malcolm Whitman; Jorge A Iñiguez-Lluhí
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

Review 2.  The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease.

Authors:  Kun Ping Lu; Xiao Zhen Zhou
Journal:  Nat Rev Mol Cell Biol       Date:  2007-11       Impact factor: 94.444

3.  Regulation of FOXC1 stability and transcriptional activity by an epidermal growth factor-activated mitogen-activated protein kinase signaling cascade.

Authors:  Fred B Berry; Farideh Mirzayans; Michael A Walter
Journal:  J Biol Chem       Date:  2006-02-21       Impact factor: 5.157

4.  Conditional transgene expression in endothelial cells.

Authors:  R Sarao; D J Dumont
Journal:  Transgenic Res       Date:  1998-11       Impact factor: 2.788

5.  Foxc2 is a common mediator of insulin and transforming growth factor beta signaling to regulate plasminogen activator inhibitor type I gene expression.

Authors:  Hideo Fujita; Myengmo Kang; Mesut Eren; Linda A Gleaves; Douglas E Vaughan; Tsutomu Kume
Journal:  Circ Res       Date:  2006-02-02       Impact factor: 17.367

6.  Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3.

Authors:  T Mäkinen; T Veikkola; S Mustjoki; T Karpanen; B Catimel; E C Nice; L Wise; A Mercer; H Kowalski; D Kerjaschki; S A Stacker; M G Achen; K Alitalo
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

7.  Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia.

Authors:  M Laitinen; K Mäkinen; H Manninen; P Matsi; M Kossila; R S Agrawal; T Pakkanen; J S Luoma; H Viita; J Hartikainen; E Alhava; M Laakso; S Ylä-Herttuala
Journal:  Hum Gene Ther       Date:  1998-07-01       Impact factor: 5.695

8.  Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24.

Authors:  G Brice; S Mansour; R Bell; J R O Collin; A H Child; A F Brady; M Sarfarazi; K G Burnand; S Jeffery; P Mortimer; V A Murday
Journal:  J Med Genet       Date:  2002-07       Impact factor: 6.318

9.  Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences.

Authors:  Jeremy Goecks; Anton Nekrutenko; James Taylor
Journal:  Genome Biol       Date:  2010-08-25       Impact factor: 13.583

10.  FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1.

Authors:  Camilla Norrmén; Konstantin I Ivanov; Jianpin Cheng; Nadine Zangger; Mauro Delorenzi; Muriel Jaquet; Naoyuki Miura; Pauli Puolakkainen; Valerie Horsley; Junhao Hu; Hellmut G Augustin; Seppo Ylä-Herttuala; Kari Alitalo; Tatiana V Petrova
Journal:  J Cell Biol       Date:  2009-04-27       Impact factor: 10.539

View more
  18 in total

1.  FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature.

Authors:  Amélie Sabine; Esther Bovay; Cansaran Saygili Demir; Wataru Kimura; Muriel Jaquet; Yan Agalarov; Nadine Zangger; Joshua P Scallan; Werner Graber; Elgin Gulpinar; Brenda R Kwak; Taija Mäkinen; Inés Martinez-Corral; Sagrario Ortega; Mauro Delorenzi; Friedemann Kiefer; Michael J Davis; Valentin Djonov; Naoyuki Miura; Tatiana V Petrova
Journal:  J Clin Invest       Date:  2015-09-21       Impact factor: 14.808

2.  Cdk5 controls lymphatic vessel development and function by phosphorylation of Foxc2.

Authors:  Johanna Liebl; Siwei Zhang; Markus Moser; Yan Agalarov; Cansaran Saygili Demir; Bianca Hager; James A Bibb; Ralf H Adams; Friedemann Kiefer; Naoyuki Miura; Tatiana V Petrova; Angelika M Vollmar; Stefan Zahler
Journal:  Nat Commun       Date:  2015-06-01       Impact factor: 14.919

Review 3.  Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective.

Authors:  Kristian M Hargadon; Travis B Goodloe; Nathaniel D Lloyd
Journal:  Cancer Metastasis Rev       Date:  2022-06-14       Impact factor: 9.264

4.  Mechanisms of Connexin-Related Lymphedema.

Authors:  Jorge A Castorena-Gonzalez; Scott D Zawieja; Min Li; R Sathish Srinivasan; Alexander M Simon; Cor de Wit; Roger de la Torre; Luis A Martinez-Lemus; Grant W Hennig; Michael J Davis
Journal:  Circ Res       Date:  2018-09-28       Impact factor: 17.367

5.  Lymph flow regulates collecting lymphatic vessel maturation in vivo.

Authors:  Daniel T Sweet; Juan M Jiménez; Jeremy Chang; Paul R Hess; Patricia Mericko-Ishizuka; Jianxin Fu; Lijun Xia; Peter F Davies; Mark L Kahn
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

6.  Endothelial immune activation programmes cell-fate decisions and angiogenesis by inducing angiogenesis regulator DLL4 through TLR4-ERK-FOXC2 signalling.

Authors:  Sheng Xia; Heather L Menden; Thomas R Korfhagen; Tsutomu Kume; Venkatesh Sampath
Journal:  J Physiol       Date:  2018-03-02       Impact factor: 5.182

7.  Imbalance between Expression of FOXC2 and Its lncRNA in Lymphedema-Distichiasis Caused by Frameshift Mutations.

Authors:  Sara Missaglia; Daniela Tavian; Sandro Michelini; Paolo Enrico Maltese; Andrea Bonanomi; Matteo Bertelli
Journal:  Genes (Basel)       Date:  2021-04-27       Impact factor: 4.096

8.  Foxc1 and Foxc2 deletion causes abnormal lymphangiogenesis and correlates with ERK hyperactivation.

Authors:  Anees Fatima; Ying Wang; Yutaka Uchida; Pieter Norden; Ting Liu; Austin Culver; William H Dietz; Ford Culver; Meredith Millay; Yoh-Suke Mukouyama; Tsutomu Kume
Journal:  J Clin Invest       Date:  2016-05-23       Impact factor: 14.808

9.  FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.

Authors:  Mika Pietilä; Geraldine V Vijay; Rama Soundararajan; Xian Yu; William F Symmans; Nathalie Sphyris; Sendurai A Mani
Journal:  Sci Rep       Date:  2016-04-11       Impact factor: 4.379

10.  Cdk5 and Foxc2--a new relationship in the lymphatic vasculature.

Authors:  Johanna Liebl
Journal:  Oncotarget       Date:  2015-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.